Sigyn Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

EARNINGS PER SHARE (Tables)

3 Months Ended

Mar. 31, 2018

The following table sets forth the computation of basic and diluted net income per share:

	For the Three Months			For the Three Months
	Ended March 31,			Ended March 31,
	2018			2017

Net loss attributable to the common stockholders	$	(739,392	)	$	(613,895	)

Basic weighted average outstanding shares of common stock		57,711,496			43,704,883
Dilutive effect of options and warrants		—			—
Diluted weighted average common stock and common stock equivalents		57,711,496			43,704,883
Loss per share:
Basic and diluted	$	(0.01	)	$	(0.01	)